TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29742136

Group type: EXPERIMENTAL
Intervention: PLA plus food (10 kg/month of fortified wheat-soya 'Super Cereal')
Number of subjects: 25092

Group type: EXPERIMENTAL
Intervention: PLA only
Number of subjects: 25092

Group type: EXPERIMENTAL
Intervention: PLA plus cash (NPR750≈US$7.5/month)
Number of subjects: 25092

Group type: COMPARATOR
Intervention: Control (existing government programmes)
Number of subjects: 25092

Group type: EXPERIMENTAL
Intervention: PLA plus cash
Number of subjects: 25092

Group type: EXPERIMENTAL
Intervention: PLA plus food
Number of subjects: 25092
Study: 26820618

Group type: EXPERIMENTAL
Intervention: Everolimus (3-6 ng/mL) with reduced-exposure calcineurin inhibitor (CNI; cyclosporine) to weeks 7-11 after transplant, followed by increased everolimus exposure (target 6-10 ng/mL) with cyclosporine withdrawal
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard-exposure cyclosporine
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 115

Group type: COMPARATOR
Intervention: CNI-treated patients
Number of subjects: 115
Study: 26215945

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 2923

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2923
Study: 23896830

Group type: COMPARATOR
Intervention: Mild therapeutic hypothermia (target temperature of 33°C) alone (n=17)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Xenon inhalation combined with mild therapeutic hypothermia (target concentration of at least 40%) (n=16)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Xenon inhalation combined with mild therapeutic hypothermia (n=16)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups (n=33 total evaluable patients)
Number of subjects: 36
Study: 20795925

Group type: EXPERIMENTAL
Intervention: Student-led progressive resistance training program (6 exercises using weight machines, performed twice a week for 10 weeks, 3 sets of 12 repetitions or until fatigue)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 23
Study: 17703101

Group type: EXPERIMENTAL
Intervention: Skin prick test at a concentration of 1 mg/ml
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intradermal test at a concentration of 0.1 mg/ml
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Skin test administered before chemotherapy
Number of subjects: 29
Study: 17140177

Group type: EXPERIMENTAL
Intervention: B-vitamin combinations (cyanocobolamid, folic acid, and pyridoxine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14727246

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy with weekly carboplatin/paclitaxel and daily subcutaneous amifostine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy with weekly carboplatin/paclitaxel without daily subcutaneous amifostine
Number of subjects: 0
Study: 9878932

Group type: EXPERIMENTAL
Intervention: Desirudin (r-hirudin)
Number of subjects: 11142

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 11142

Group type: EXPERIMENTAL
Intervention: ST-segment elevation
Number of subjects: 11142

Group type: EXPERIMENTAL
Intervention: No ST-segment elevation
Number of subjects: 11142
Study: 7720448

Group type: EXPERIMENTAL
Intervention: Clindamycin and Gentacoll
Number of subjects: 107

Group type: COMPARATOR
Intervention: Clindamycin (control)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Gentacoll and Clindamycin
Number of subjects: 107
Study: 2116817

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 6892751

Group type: EXPERIMENTAL
Intervention: Lactose free milk
Number of subjects: 341

Group type: COMPARATOR
Intervention: Regular milk
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Lactose enriched milk
Number of subjects: 341
Study: 31832636

Group type: EXPERIMENTAL
Intervention: Urogenital schistosomiasis (egg positive and/or hematuria positive)
Number of subjects: 4437
Study: 31576651

Group type: EXPERIMENTAL
Intervention: Combined video game distraction and anesthesia mask exposure and shaping intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional preoperative preparation (Control)
Number of subjects: 128
Study: 29653193

Group type: EXPERIMENTAL
Intervention: MTZ + AMX
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: aPDT
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 26999504

Group type: EXPERIMENTAL
Intervention: OurRelationship program (8‐hr online program with 4 15‐min calls)
Number of subjects: 600
Study: 24713632

Group type: EXPERIMENTAL
Intervention: Normocaloric diet (28-week program based on normal requirements for height and meal planning)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Normocaloric diet
Number of subjects: 51

Group type: COMPARATOR
Intervention: Free diet (control group)
Number of subjects: 51
Study: 23097398

Group type: EXPERIMENTAL
Intervention: Large FSH dose (150 mg, n=18)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Medium FSH dose (130 mg, n=12)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Small FSH dose (80 mg, n=7)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (saline, n=6)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Large FSH (n=11)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (n=10)
Number of subjects: 37
Study: 20504378

Group type: EXPERIMENTAL
Intervention: Etoricoxib (preemptive analgesia)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Etoricoxib (postoperative analgesia)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (preemptive analgesia)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (postoperative analgesia)
Number of subjects: 120
Study: 18400710

Group type: COMPARATOR
Intervention: 1 cup of black tea
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2 cups of black tea
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at molar ratio to iron 2:1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at molar ratio to iron 4:1
Number of subjects: 20
Study: 16618293

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg x kg(‐1) preceded by fentanyl 3.0 microg x kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 3.0 mg x kg(‐1) preceded by fentanyl 3.0 microg x kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 3.5 mg x kg(‐1) preceded by fentanyl 3.0 microg x kg(‐1)
Number of subjects: 60
Study: 14667958

Group type: EXPERIMENTAL
Intervention: NNT of 10
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: NNT of 50
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: NNT of 100
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: NNT of 400
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Postponement of hip fracture by 1 month
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Postponement of hip fracture by 6 months
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Postponement of hip fracture by 1 year
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Postponement of hip fracture by 4 years
Number of subjects: 967
Study: 10465703

Group type: EXPERIMENTAL
Intervention: Vibrating forefoot and rear foot zones separately
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-stimulating forefoot and rear foot zones at different frequencies
Number of subjects: 0
Study: 8896529

Group type: EXPERIMENTAL
Intervention: DTPa vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTPw vaccine
Number of subjects: 0
Study: 2010737

Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colloids
Number of subjects: 0
Study: 7068935

Group type: EXPERIMENTAL
Intervention: Erythromycin base (250 mg, four times a day for six days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (250 mg, four times a day for six days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (250 mg, four times a day for six days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lactose placebo (control group, 250 mg, four times a day for six days)
Number of subjects: 23
Study: 4061890

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day (n = 20)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Tamoxifen or placebo (n = 54)
Number of subjects: 74
Study: 29927496

Group type: EXPERIMENTAL
Intervention: Family-strengthening intervention (10 weeks of relationship education services)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no services)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-strengthening intervention
Number of subjects: 0
Study: 27956763

Group type: EXPERIMENTAL
Intervention: Oral immunonutrition (IN)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Oral standard nutrition (Control)
Number of subjects: 244
Study: 24783221

Group type: EXPERIMENTAL
Intervention: Ultrarush therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional preseasonal SIT
Number of subjects: 22
Study: 22212646

Group type: EXPERIMENTAL
Intervention: 1500 μg vitamin D₃ (group 1)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Two doses of 3000 μg vitamin D₃ (group 2)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care (non-supplemented group)
Number of subjects: 97
Study: 20974030

Group type: EXPERIMENTAL
Intervention: Belladonna and opium (B & O) suppository
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 99
Study: 18411239

Group type: EXPERIMENTAL
Intervention: CD-ROM
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Book
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 53
Study: 15605190

Group type: EXPERIMENTAL
Intervention: Clodronate (800 mg daily for 2 years)
Number of subjects: 59
Study: 12408892

Group type: EXPERIMENTAL
Intervention: Nefopam (NEF) and desmethyl-nefopam (DMN) assayed using HPLC with a mobile phase of buffer and acetonitrile, flow rate 1.5 ml/min.
Number of subjects: 0
Study: 10885083

Group type: EXPERIMENTAL
Intervention: Written agenda forms completed by patients
Number of subjects: 819
Study: 7573921

Group type: EXPERIMENTAL
Intervention: Group A (EM/LIG) - EMLA and intradermal and subdermal 1% lignocaine infiltration
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Group B (EM/SAL) - EMLA and saline
Number of subjects: 83

Group type: COMPARATOR
Intervention: Group C (PL/LIG) - Placebo cream and 1% lignocaine
Number of subjects: 83
Study: 1976549

Group type: EXPERIMENTAL
Intervention: Lamicel tent preoperative treatment
Number of subjects: 629

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 629
Study: 7283035

Group type: EXPERIMENTAL
Intervention: Topical hydrogen peroxide
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control (no topical hydrogen peroxide)
Number of subjects: 217
Study: 31379101

Group type: EXPERIMENTAL
Intervention: Test formulation of teriflunomide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference formulation of teriflunomide
Number of subjects: 14
Study: 29545413

Group type: EXPERIMENTAL
Intervention: 0.1% ciclosporin A cationic emulsion (CsA CE)
Number of subjects: 734
Study: 30072191

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100 mg/m2) followed by FEC
Number of subjects: 152

Group type: COMPARATOR
Intervention: Docetaxel followed by FEC
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100 mg/m2)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Number of subjects: 152
Study: 26822209

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin administered for 7 consecutive days
Number of subjects: 210

Group type: COMPARATOR
Intervention: Matching placebo administered for 7 consecutive days
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 210
Study: 24961471

Group type: EXPERIMENTAL
Intervention: 4 ml of human fibrin sealant (Tisseel™, Baxter(®) Deerfield, IL, USA) sprayed along the suture line
Number of subjects: 100

Group type: COMPARATOR
Intervention: No fibrin sealant
Number of subjects: 100
Study: 22146491

Group type: EXPERIMENTAL
Intervention: Antivenom A (F(ab')2 fragments)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Antivenom B (whole IgG molecules)
Number of subjects: 100
Study: 20637495

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18198641

Group type: EXPERIMENTAL
Intervention: Aidi Injection (ADI) combined with FOLFOX4 regimen
Number of subjects: 117

Group type: COMPARATOR
Intervention: FOLFOX4 regimen alone
Number of subjects: 117
Study: 16375790

Group type: EXPERIMENTAL
Intervention: Health technology assessment (HTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telehealth evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participatory strategy
Number of subjects: 0
Study: 10673673

Group type: EXPERIMENTAL
Intervention: Mobilization chemotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ceprate SC selection
Number of subjects: 39
Study: 9496390

Group type: EXPERIMENTAL
Intervention: Pamidronate 120 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 52
Study: 8347065

Group type: EXPERIMENTAL
Intervention: Elbow joint restriction using a splint
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unrestricted elbow joint motion
Number of subjects: 19
Study: 3519766

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide twice daily for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30125353

Group type: EXPERIMENTAL
Intervention: Ivermectin 300 mcg/kg/day plus Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ivermectin 600 mcg/kg/day plus Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ivermectin 0 mcg/kg/day plus Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ivermectin (all doses)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 141
Study: 27232116

Group type: EXPERIMENTAL
Intervention: Belatacept-based immunosuppression
Number of subjects: 100

Group type: COMPARATOR
Intervention: CsA-based immunosuppression
Number of subjects: 100
Study: 25945337

Group type: EXPERIMENTAL
Intervention: Liothyronine (50 mcg every morning)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23432361

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg day(-1)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 22124043

Group type: EXPERIMENTAL
Intervention: Periosteal membrane as a barrier
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (mucoperiosteal flap sutured back after debridement)
Number of subjects: 12
Study: 18691337

Group type: EXPERIMENTAL
Intervention: LC-PUFA supplementation (including DHA and AA)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Control group (formula milk without LC-PUFA)
Number of subjects: 901
Study: 16533938

Group type: EXPERIMENTAL
Intervention: Abciximab (0.25 mg/kg bolus, followed by 0.125 microg/kg/min infusion for 12 hours, plus heparin, 70 U/kg)
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Placebo (placebo bolus and infusion for 12 hours, plus heparin bolus, 140 U/kg)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2022
Study: 14712149

Group type: EXPERIMENTAL
Intervention: Comprehensive cleaning
Number of subjects: 114

Group type: COMPARATOR
Intervention: Superficial cleaning (control)
Number of subjects: 114
Study: 11155088

Group type: EXPERIMENTAL
Intervention: 3 IU GH/m2/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 6 IU GH/m2/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 79
Study: 9059953

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (400 mg daily for 2 weeks) + calcium (500 mg daily for 11 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate + calcium
Number of subjects: 12
Study: 8104201

Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3080726

Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride predominant formula (46% medium-chain, 54% long-chain)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Long-chain fatty acid predominant formula (4% medium-chain, 96% long-chain)
Number of subjects: 13
Study: 29528986

Group type: COMPARATOR
Intervention: Quadrivalent human papillomavirus vaccine (qHPV; types 6, 11, 16, 18)
Number of subjects: 575
Study: 27683073

Group type: EXPERIMENTAL
Intervention: Monophasic bone substitute (MBS) - 100% s-TCP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Biphasic bone substitute (BBS) - 60% HA and 40% s-TCP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Biphasic bone substitute (BBS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Monophasic bone substitute (MBS)
Number of subjects: 60
Study: 25634117

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (4-12 mg/h)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 70
Study: 22223124

Group type: EXPERIMENTAL
Intervention: High-intensity smoking cessation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medium-intensity smoking cessation intervention
Number of subjects: 0
Study: 21371155

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) with a selection box containing patch, gum, inhaler, sublingual tablet, oral pouch for 8 weeks after a week of familiarization.
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Usual Quitline care (control group).
Number of subjects: 1410
Study: 18372218

Group type: EXPERIMENTAL
Intervention: High frequency exercise (3 endurance resistance exercises and cycle ergometer training for 30 min, 5 times a week for 8 months at 70% of VO(2max))
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 37
Study: 17158427

Group type: EXPERIMENTAL
Intervention: RRR‐alpha‐tocopheryl acetate
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: all‐rac‐alpha‐tocopheryl acetate
Number of subjects: 1
Study: 12659475

Group type: EXPERIMENTAL
Intervention: 5‐s isometric contraction (5‐IC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 10‐s isometric contraction (10‐IC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 11117766

Group type: EXPERIMENTAL
Intervention: Total Abdominal Hysterectomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Laparoscopic Assisted Vaginal Hysterectomy
Number of subjects: 120
Study: 8061530

Group type: EXPERIMENTAL
Intervention: Testing against Flaviviridae viruses (yellow fever, dengue type 1 and 2, West Nile, Wesselsbron) using haemagglutination inhibition test
Number of subjects: 2507

Group type: COMPARATOR
Intervention: Previous serosurvey from 1971
Number of subjects: 2507
Study: 2898045

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (7.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon
Number of subjects: 12
Study: 30950580

Group type: EXPERIMENTAL
Intervention: 12 mg Lutein and Zeaxanthin (L+Z)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27925283

Group type: EXPERIMENTAL
Intervention: Haloperidol (4 mg oral dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26156311

Group type: EXPERIMENTAL
Intervention: Transbronchial needle aspiration (TBNA) and transbronchial catheter aspiration (TBCA) combined
Number of subjects: 46

Group type: COMPARATOR
Intervention: Transbronchial forceps biopsy (TBB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All modalities (TBB, TBNA, TBCA)
Number of subjects: 46
Study: 23549100

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab and dexamethasone combination therapy (Group 1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab monotherapy (Group 2)
Number of subjects: 37
Study: 21421574

Group type: COMPARATOR
Intervention: Fluoroscopy alone (Group A, 40 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroanatomic integration (Cartomerge®, Group B, 40 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroanatomic integration plus catheters visualization (Carto® 3 System, Group C, 40 patients)
Number of subjects: 120
Study: 19554090

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy aiming for LDL-cholesterol levels below 70 mg/dL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard statin therapy aiming for LDL-cholesterol levels < or =100 mg/dL
Number of subjects: 0
Study: 18093504

Group type: EXPERIMENTAL
Intervention: Calcaneous ultrasound bone mineral density (BMD) measurement using Achilles Express(R)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Dual energy x-ray absorptiometry (DXA)
Number of subjects: 146
Study: 15199111

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1200 mg/day)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study: 11748341

Group type: EXPERIMENTAL
Intervention: Etidronate therapy (discontinued after 52 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Calcium alone (500 mg/d)
Number of subjects: 114
Study: 9709143

Group type: EXPERIMENTAL
Intervention: Size 5 laryngeal mask airway
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Size 4 laryngeal mask airway
Number of subjects: 30

Group type: COMPARATOR
Intervention: Size 3 laryngeal mask airway
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oropharyngeal leak pressure for size 4 and size 5
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fiberoptic view for size 4 and size 5
Number of subjects: 30

Group type: COMPARATOR
Intervention: Height as a predictive variable
Number of subjects: 30
Study: 7751528

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray
Number of subjects: 233

Group type: COMPARATOR
Intervention: Saline solution (vehicle)
Number of subjects: 233